Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009.
The Roche/Genentech oncology pipeline includes 40 investigational cancer medicines being studied in 600 clinical trials across a dozen types of cancer.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Genentech's Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer Phase III data from the CLL11 study to ...
Autogene cevumeran is an investigational mRNA vaccine being developed jointly by BioNTech and Genentech as an adjuvant therapy in cancer treatment to prevent cancer recurrence following surgery.
Genentech previously said the use of the drug in the indication accounts for a fraction of its overall revenue. The U.S. Food and Drug Administration had granted accelerated approval to Gavreto in ...
oncology: Opdivo 7570 5763 6 pembrolizumab: oncology: Keytruda 7171 3809 7 etanercept: rheumatoid arthritis: Enbrel 7126 7885 8 trastuzumab: breast cancer: Herceptin 6981 7013 9 bevacizumab: colon cancer: Avastin 6847 6686 10 rituximab: non-Hodgkin's lymphoma: Rituxan, MabThera 6750 7298 11 rivaroxaban: anticoagulant: Xarelto 6589 6234 12 ...
Trastuzumab emtansine (ado-trastuzumab emtansine or T-DM1, trade name: Kadcyla, marketed by Genentech and Roche) was approved in February 2013 for the treatment of people with HER2-positive metastatic breast cancer (mBC) who had received prior treatment with trastuzumab and a taxane chemotherapy. [13] [14]